- Home
- PGZ vs ICCM Comparison
PGZ vs ICCM Comparison
Compare PGZ & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGZ
- ICCM
- Stock Information
- Founded
- PGZ 2012
- ICCM 2006
- Country
- PGZ United States
- ICCM Israel
- Employees
- PGZ N/A
- ICCM N/A
- Industry
- PGZ Investment Managers
- ICCM
- Sector
- PGZ Finance
- ICCM
- Exchange
- PGZ Nasdaq
- ICCM Nasdaq
- Market Cap
- PGZ 68.3M
- ICCM 75.8M
- IPO Year
- PGZ N/A
- ICCM N/A
- Fundamental
- Price
- PGZ $10.37
- ICCM $1.41
- Analyst Decision
- PGZ
- ICCM Strong Buy
- Analyst Count
- PGZ 0
- ICCM 2
- Target Price
- PGZ N/A
- ICCM $2.70
- AVG Volume (30 Days)
- PGZ 23.0K
- ICCM 379.2K
- Earning Date
- PGZ 01-01-0001
- ICCM 04-02-2025
- Dividend Yield
- PGZ 12.26%
- ICCM N/A
- EPS Growth
- PGZ N/A
- ICCM N/A
- EPS
- PGZ N/A
- ICCM N/A
- Revenue
- PGZ N/A
- ICCM $3,671,000.00
- Revenue This Year
- PGZ N/A
- ICCM $10.03
- Revenue Next Year
- PGZ N/A
- ICCM $62.68
- P/E Ratio
- PGZ N/A
- ICCM N/A
- Revenue Growth
- PGZ N/A
- ICCM 26.02
- 52 Week Low
- PGZ $8.46
- ICCM $0.48
- 52 Week High
- PGZ $10.59
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- PGZ 59.45
- ICCM 60.09
- Support Level
- PGZ $10.35
- ICCM $1.22
- Resistance Level
- PGZ $10.49
- ICCM $1.66
- Average True Range (ATR)
- PGZ 0.09
- ICCM 0.09
- MACD
- PGZ 0.01
- ICCM 0.01
- Stochastic Oscillator
- PGZ 77.86
- ICCM 43.18
About PGZ Principal Real Estate Income Fund of Beneficial Interest
Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities. The company does its investments in USA, Australia, Japan, France, Great Britain, Canada, Hong Kong, Germany, Singapore, South Korea, British Virgin Islands and more.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.